Hogan Lovells US LLP
Heterocyclic inhibitors of MEK and methods of use thereof
Disclosed are compounds of the Formula Iand pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, and W are as defined in the specification. Such compounds are MEK inhibitors and are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, and inflammatory conditions in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative and inflammatory diseases in mammals and pharmaceutical compositions containing such compounds.
Array BioPharma Inc.
C C C A A C A A A C C A A A A C C C C C A C A C C A A A C A A A A A
C07D C07D C07D A61K A61P C07D A61P A61K A61K C07D C07D A61P A61K A61K A61K C07D C07D C07D C07D C07D A61K C07D A61P C07D C07D A61K A61P A61P C07D A61P A61P A61P A61K A61K
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Joseph P. James Jeongbeob Allison L. Hong Woon Eli M.
Lyssikatos Blake Seo Marlow Yang Wallace